Nektar Therapeutics Soars 29.56% on Skin Drug Hype

On June 24, 2025, Nektar Therapeutics surged 29.56% in pre-market trading, marking a significant rise in its stock price.

Nektar Therapeutics' stock experienced a notable rally after hours on June 23, 2025, driven by anticipation of major results from its skin drug Rezpegaldesleukin. The company's announcement on June 23 highlighted the potential of this drug, which is being studied for its efficacy in treating various skin conditions. This news has generated considerable excitement among investors, leading to a substantial increase in the stock's value.

Investors are closely watching the developments surrounding Rezpegaldesleukin, as positive results could further boost Nektar Therapeutics' market position and attract more investment. The company's focus on innovative drug development continues to be a key driver of its stock performance, with investors optimistic about its future prospects.